{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:13:17Z","timestamp":1788858797314,"version":"build-2803163510"},"reference-count":175,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Epigenetic dysregulation is a hallmark of glioblastoma (GBM) pathogenesis, with histone methylation playing a central role in chromatin remodeling and gene expression regulation. Enhancer of zeste homolog 2 (EZH2) is a key epigenetic regulator responsible for histone methylation. It primarily functions as a transcriptional repressor and regulates signaling pathways associated with tumor progression. Importantly, EZH2 is frequently recruited to long non-coding RNA (lncRNA) scaffolds, including HOTAIR and AGAP2-AS1, thereby enabling coordinated gene silencing by establishing repressive chromatin states. Although EZH2 expression is not consistently associated with overall survival in GBM, EZH2 remains a promising therapeutic target due to its roles in stemness and treatment resistance. This review summarizes current knowledge of EZH2 functions in normal and GBM cells, highlighting its complex functions and therapeutic potential. We also discuss the current status and limitations of EZH2-targeting therapies, including challenges related to blood\u2013brain barrier penetration and clinical translation. Although a combination of EZH2 inhibitors and other epigenetic inhibitors may be beneficial in selected molecular contexts, its rationale depends on the underlying regulatory network. Future therapeutic development will require biomarker-driven patient stratification and precision medicine approaches to maximize clinical benefit in GBM.<\/jats:p>","DOI":"10.3390\/ijms27177749","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:48:36Z","timestamp":1788256116000},"page":"7749","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhancer of Zeste Homolog 2 (EZH2): From Glioblastoma Biology to Potential Epigenetic Therapy"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0276-4870","authenticated-orcid":false,"given":"Jan","family":"Grzegorzewski","sequence":"first","affiliation":[{"name":"Poznan University of Medical Sciences, Doctoral School, Bukowska 70, 60-812 Pozna\u0144, Poland"},{"name":"Poznan University of Medical Sciences, Department of Pharmaceutical Biochemistry, Rokietnicka 3, 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9230-1639","authenticated-orcid":false,"given":"Maria","family":"Lindner","sequence":"additional","affiliation":[{"name":"Poznan University of Medical Sciences, Department of Pharmaceutical Biochemistry, Rokietnicka 3, 60-806 Pozna\u0144, Poland"},{"name":"Poznan University of Medical Sciences, The Student Scientific Society Biomolekularni, 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7807-5964","authenticated-orcid":false,"given":"Dagmara","family":"Lisi\u0144ska","sequence":"additional","affiliation":[{"name":"Poznan University of Medical Sciences, Department of Pharmaceutical Biochemistry, Rokietnicka 3, 60-806 Pozna\u0144, Poland"},{"name":"Poznan University of Medical Sciences, The Student Scientific Society Biomolekularni, 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2872-8875","authenticated-orcid":false,"given":"Aleksandra","family":"Majchrzak-Celi\u0144ska","sequence":"additional","affiliation":[{"name":"Poznan University of Medical Sciences, Department of Pharmaceutical Biochemistry, Rokietnicka 3, 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Grochans, S., Cybulska, A.M., Simi\u0144ska, D., Korbecki, J., Kojder, K., Chlubek, D., and Baranowska-Bosiacka, I. (2022). Epidemiology of Glioblastoma Multiforme\u2013Literature Review. Cancers, 14.","DOI":"10.3390\/cancers14102412"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and Other Primary Brain Malignancies in Adults: A Review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Birzu, C., French, P., Caccese, M., Cerretti, G., Idbaih, A., Zagonel, V., and Lombardi, G. (2020). Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. Cancers, 13.","DOI":"10.3390\/cancers13010047"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11060-018-03015-9","article-title":"Prevalence of Symptoms in Glioma Patients throughout the Disease Trajectory: A Systematic Review","volume":"140","author":"Snijders","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_6","first-page":"50","article-title":"Glioblastoma: Epidemiology and Imaging-Based Review","volume":"108","author":"Madour","year":"2025","journal-title":"R. I. Med. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"De Vleeschouwer, S. (2017). Current Standards of Care in Glioblastoma Therapy. Glioblastoma, Codon Publications.","DOI":"10.15586\/codon.glioblastoma.2017"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-025-02267-0","article-title":"Glioblastoma Multiforme: Insights into Pathogenesis, Key Signaling Pathways, and Therapeutic Strategies","volume":"24","author":"Pouyan","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000531319","article-title":"Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques","volume":"108","author":"Czarnywojtek","year":"2023","journal-title":"Pharmacology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/BST20180444","article-title":"Glioblastoma Heterogeneity and the Tumour Microenvironment: Implications for Preclinical Research and Development of New Treatments","volume":"47","author":"Perrin","year":"2019","journal-title":"Biochem. Soc. Trans."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Becker, A.P., Sells, B.E., Haque, S.J., and Chakravarti, A. (2021). Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology. Cancers, 13.","DOI":"10.3390\/cancers13040761"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"105780","DOI":"10.1016\/j.phrs.2021.105780","article-title":"Glioblastoma Multiforme (GBM): An Overview of Current Therapies and Mechanisms of Resistance","volume":"171","author":"Wu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.gendis.2015.02.001","article-title":"Glioblastoma Stem Cells (GSCs) Epigenetic Plasticity and Interconversion between Differentiated Non-GSCs and GSCs","volume":"2","author":"Safa","year":"2015","journal-title":"Genes Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.devcel.2021.12.007","article-title":"Quiescent Human Glioblastoma Cancer Stem Cells Drive Tumor Initiation, Expansion, and Recurrence Following Chemotherapy","volume":"57","author":"Xie","year":"2022","journal-title":"Dev. Cell"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Eckerdt, F., and Platanias, L.C. (2023). Emerging Role of Glioma Stem Cells in Mechanisms of Therapy Resistance. Cancers, 15.","DOI":"10.3390\/cancers15133458"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yalamarty, S.S.K., Filipczak, N., Li, X., Subhan, M.A., Parveen, F., Ataide, J.A., Rajmalani, B.A., and Torchilin, V.P. (2023). Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM). Cancers, 15.","DOI":"10.3390\/cancers15072116"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Di Nunno, V., Franceschi, E., Tosoni, A., Gatto, L., Bartolini, S., and Brandes, A.A. (2022). Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.852950"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/CCO.0000000000000990","article-title":"Unveiling the Enigma of the Blood-Brain Barrier in Glioblastoma: Current Advances from Preclinical and Clinical Studies","volume":"35","author":"Ahmed","year":"2023","journal-title":"Curr. Opin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc3918","article-title":"Heterogeneity of Epidermal Growth Factor Receptor Signalling Networks in Glioblastoma","volume":"15","author":"Furnari","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"106510","DOI":"10.1016\/j.phrs.2022.106510","article-title":"CRISPR\/Cas9-Induced Knockout Reveals the Role of ABCB1 in the Response to Temozolomide, Carmustine and Lomustine in Glioblastoma Multiforme","volume":"185","author":"Radtke","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"El Khayari, A., Bouchmaa, N., Taib, B., Wei, Z., Zeng, A., and El Fatimy, R. (2022). Metabolic Rewiring in Glioblastoma Cancer: EGFR, IDH and Beyond. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.901951"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Olympios, N., Gilard, V., Marguet, F., Clatot, F., Di Fiore, F., and Fontanilles, M. (2021). TERT Promoter Alterations in Glioblastoma: A Systematic Review. Cancers, 13.","DOI":"10.3390\/cancers13051147"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1245\/s10434-013-3380-0","article-title":"Gain of Function of Mutant TP53 in Glioblastoma: Prognosis and Response to Temozolomide","volume":"21","author":"Wang","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., and Saoud, K. (2018). The P53 Pathway in Glioblastoma. Cancers, 10.","DOI":"10.3390\/cancers10090297"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1038\/onc.2016.493","article-title":"Characterization of PTEN Mutations in Brain Cancer Reveals That Pten Mono-Ubiquitination Promotes Protein Stability and Nuclear Localization","volume":"36","author":"Yang","year":"2017","journal-title":"Oncogene"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11060-025-05049-2","article-title":"Do the Benefits of IDH Mutations in High-Grade Glioma Persist beyond the First Recurrence? A Multi-Institutional Retrospective Analysis","volume":"174","author":"Lally","year":"2025","journal-title":"J. Neurooncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10048-024-00793-5","article-title":"Epigenetic Dysregulation in Glioblastoma: Potential Pathways to Precision Medicine","volume":"26","author":"Prakash","year":"2024","journal-title":"Neurogenetics"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Shahani, A., Slika, H., Elbeltagy, A., Lee, A., Peters, C., Dotson, T., Raj, D., and Tyler, B. (2025). The Epigenetic Mechanisms Involved in the Treatment Resistance of Glioblastoma. Cancer Drug Resist, 8.","DOI":"10.20517\/cdr.2024.157"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Amirmahani, F., Kumar, S., and Muthukrishnan, S.D. (2025). Epigenetic Mechanisms of Plasticity and Resistance in Glioblastoma: Therapeutic Targets and Implications. Front. Epigenet. Epigenom., 3.","DOI":"10.3389\/freae.2025.1519449"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Meleiro, M., and Henrique, R. (2025). Epigenetic Alterations in Glioblastoma Multiforme as Novel Therapeutic Targets: A Scoping Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26125634"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Majchrzak-Celi\u0144ska, A., Warych, A., and Szoszkiewicz, M. (2021). Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing. Genes, 12.","DOI":"10.3390\/genes12020208"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lindner, M., Lisi\u0144ska, D., K\u0119dzierzy\u0144ska, A., and Majchrzak-Celi\u0144ska, A. (2026). Targeting BRD4-A Promising Therapeutic Option for Glioblastoma?. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27052268"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1002\/1878-0261.13706","article-title":"Unravelling the Mosaic: Epigenetic Diversity in Glioblastoma","volume":"18","author":"Lucchini","year":"2024","journal-title":"Mol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gibson, D., Vo, A.H., Lambing, H., Bhattacharya, P., Tahir, P., Chehab, F.F., and Butowski, N. (2024). A Systematic Review of High Impact CpG Sites and Regions for MGMT Methylation in Glioblastoma [A Systematic Review of MGMT Methylation in GBM]. BMC Neurol., 24.","DOI":"10.1186\/s12883-024-03605-3"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3892\/mco.2024.2757","article-title":"Emerging Applications of Hypomethylating Agents in the Treatment of Glioblastoma (Review)","volume":"21","author":"Inocencio","year":"2024","journal-title":"Mol. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1007\/s13277-014-3025-3","article-title":"The Methylation of a Panel of Genes Differentiates Low-Grade from High-Grade Gliomas","volume":"36","author":"Paluszczak","year":"2015","journal-title":"Tumour Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/cns.13443","article-title":"DNA Methylation Analysis with Methylation-Sensitive High-Resolution Melting (MS-HRM) Reveals Gene Panel for Glioma Characteristics","volume":"26","author":"Dybska","year":"2020","journal-title":"CNS Neurosci. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s13353-013-0149-x","article-title":"Detection of MGMT, RASSF1A, p15INK4B, and p14ARF Promoter Methylation in Circulating Tumor-Derived DNA of Central Nervous System Cancer Patients","volume":"54","author":"Paluszczak","year":"2013","journal-title":"J. Appl. Genet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s13353-015-0312-7","article-title":"Wnt Pathway Antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, Are Methylated in Gliomas and SFRP1 Methylation Predicts Shorter Survival","volume":"57","author":"Barciszewska","year":"2016","journal-title":"J. Appl. Genet"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Barnett, A.E., Ozair, A., Bamashmos, A.S., Li, H., Bosler, D.S., Yeaney, G., Ali, A., Peereboom, D.M., Lathia, J.D., and Ahluwalia, M.S. (2024). MGMT Methylation and Differential Survival Impact by Sex in Glioblastoma. Cancers, 16.","DOI":"10.3390\/cancers16071374"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of Chromatin by Histone Modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/CCO.0000000000000390","article-title":"Targeting EZH2 in Cancer Therapy","volume":"29","author":"Yamagishi","year":"2017","journal-title":"Curr. Opin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The Polycomb Complex PRC2 and Its Mark in Life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"9211","DOI":"10.1158\/0008-5472.CAN-09-1622","article-title":"EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance","volume":"69","author":"Riggi","year":"2009","journal-title":"Cancer Res."},{"key":"ref_46","first-page":"175","article-title":"Diverse Involvement of EZH2 in Cancer Epigenetics","volume":"7","author":"Dupret","year":"2015","journal-title":"Am. J. Transl. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ccr.2013.04.008","article-title":"Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells","volume":"23","author":"Kim","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"59360","DOI":"10.18632\/oncotarget.10661","article-title":"Small Molecule Epigenetic Screen Identifies Novel EZH2 and HDAC Inhibitors That Target Glioblastoma Brain Tumor-Initiating Cells","volume":"7","author":"Grinshtein","year":"2016","journal-title":"Oncotarget"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"119254","DOI":"10.1016\/j.biopha.2026.119254","article-title":"EZH2 Inhibition in Resistant Glioblastoma Stem Cells Counteracts Oxidative Stress Protection and Triggers Ferroptosis","volume":"198","author":"Doualle","year":"2026","journal-title":"Biomed. Pharmacother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e011650","DOI":"10.1136\/jitc-2025-011650","article-title":"EZH2 Inhibition and 5-Azacytidine Enhance Antitumor Immunity in PTEN-Deficient Glioblastoma by Activation Viral Mimicry Response","volume":"13","author":"Zhu","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/neuonc\/now247","article-title":"GlioVis Data Portal for Visualization and Analysis of Brain Tumor Expression Datasets","volume":"19","author":"Bowman","year":"2017","journal-title":"Neuro-Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.molcel.2013.02.013","article-title":"Occupying Chromatin: Polycomb Mechanisms for Getting to Genomic Targets, Stopping Transcriptional Traffic, and Staying Put","volume":"49","author":"Simon","year":"2013","journal-title":"Mol. Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in Cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","article-title":"Epigenetic Regulation of Cancer Progression by EZH2: From Biological Insights to Therapeutic Potential","volume":"6","author":"Gan","year":"2018","journal-title":"Biomark. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4143\/crt.2014.46.3.209","article-title":"Regulation and Role of EZH2 in Cancer","volume":"46","author":"Yamaguchi","year":"2014","journal-title":"Cancer Res. Treat."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"11316","DOI":"10.1038\/ncomms11316","article-title":"Structural Basis of Oncogenic Histone H3K27M Inhibition of Human Polycomb Repressive Complex 2","volume":"7","author":"Justin","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Antonysamy, S., Condon, B., Druzina, Z., Bonanno, J.B., Gheyi, T., Zhang, F., MacEwan, I., Zhang, A., Ashok, S., and Rodgers, L. (2013). Structural Context of Disease-Associated Mutations and Putative Mechanism of Autoinhibition Revealed by X-Ray Crystallographic Analysis of the EZH2-SET Domain. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0084147"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrm4067","article-title":"Targeting Polycomb Systems to Regulate Gene Expression: Modifications to a Complex Story","volume":"16","author":"Blackledge","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1080\/10428194.2018.1430795","article-title":"Enhancer of Zeste Homolog 2 (EZH2) Inhibitors","volume":"59","author":"Gulati","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cell.2014.02.030","article-title":"Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells","volume":"157","author":"Rheinbay","year":"2014","journal-title":"Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrm3327","article-title":"Molecular Mechanisms and Potential Functions of Histone Demethylases","volume":"13","author":"Kooistra","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Liu, H., Sun, Y., Qi, X., Gordon, R.E., O\u2019Brien, J.A., Yuan, H., Zhang, J., Wang, Z., Zhang, M., and Song, Y. (2019). EZH2 Phosphorylation Promotes Self-Renewal of Glioma Stem-Like Cells Through NF-\u03baB Methylation. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00641"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"174177","DOI":"10.1016\/j.ejphar.2021.174177","article-title":"EZH2 Regulates the Malignancy of Human Glioblastoma Cells via Modulation of Twist mRNA Stability","volume":"904","author":"Zhai","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Chien, Y.-C., Chen, J.-N., Chen, Y.-H., Chou, R.-H., Lee, H.-C., and Yu, Y.-L. (2020). Epigenetic Silencing of miR-9 Promotes Migration and Invasion by EZH2 in Glioblastoma Cells. Cancers, 12.","DOI":"10.3390\/cancers12071781"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41416-020-01032-y","article-title":"E2F7\u2212EZH2 Axis Regulates PTEN\/AKT\/mTOR Signalling and Glioblastoma Progression","volume":"123","author":"Yang","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"153003","DOI":"10.1016\/j.bbrc.2025.153003","article-title":"SHANK1 Is Epigenetically Silenced by EZH2 and Suppresses Wnt\/\u03b2-Catenin Signaling to Inhibit Glioblastoma Stem Cell Maintenance","volume":"793","author":"Liu","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"45134","DOI":"10.18632\/oncotarget.9761","article-title":"EZH2 Promotes Metabolic Reprogramming in Glioblastomas through Epigenetic Repression of EAF2-HIF1\u03b1 Signaling","volume":"7","author":"Pang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"166534","DOI":"10.1016\/j.bbadis.2022.166534","article-title":"Single-Cell RNA Sequencing Reveals Intra-Tumoral Heterogeneity of Glioblastoma and a pro-Tumor Subset of Tumor-Associated Macrophages Characterized by EZH2 Overexpression","volume":"1868","author":"Chen","year":"2022","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s00221-023-06693-8","article-title":"Targeting EZH2 Regulates the Biological Characteristics of Glioma Stem Cells via the Notch1 Pathway","volume":"241","author":"Zhao","year":"2023","journal-title":"Exp. Brain Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11060-024-04726-y","article-title":"TRIM37 Interacts with EZH2 to Epigenetically Suppress PTCH1 and Regulate Stemness in Glioma Stem Cells through Sonic Hedgehog Pathway","volume":"169","author":"Cai","year":"2024","journal-title":"J. Neurooncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s10020-024-00857-0","article-title":"Unveiling the Therapeutic Potential of IHMT-337 in Glioma Treatment: Targeting the EZH2-SLC12A5 Axis","volume":"30","author":"Zhang","year":"2024","journal-title":"Mol. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nature04431","article-title":"The Polycomb Group Protein EZH2 Directly Controls DNA Methylation","volume":"439","author":"Brenner","year":"2006","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1007\/s00210-025-04528-7","article-title":"Epigenetic Regulation of EZH2 by ncRNAs: Mechanisms and Oncogenic Implications","volume":"399","author":"Abed","year":"2026","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_74","first-page":"3204","article-title":"EZH2-Mediated H3K27me3 Enrichment on the lncRNA MEG3 Promoter Regulates the Growth and Metastasis of Glioma Cells by Regulating miR-21-3p","volume":"24","author":"Qin","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10616-021-00471-6","article-title":"LncRNA-NNT-AS1 Contributes to the Progression of Glioma by miR-582-5p\/EZH2 Axis","volume":"73","author":"Pan","year":"2021","journal-title":"Cytotechnology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3892\/ol.2021.12826","article-title":"lncRNA SNHG7 Promotes Cell Proliferation in Glioma by Acting as a Competing Endogenous RNA and Sponging miR-138-5p to Regulate EZH2 Expression","volume":"22","author":"Deng","year":"2021","journal-title":"Oncol. Lett."},{"key":"ref_77","first-page":"380","article-title":"EZH2-Mediated Long-Chain Non-Coding RNA LINC00963 Promotes Proliferation and Invasion of Glioma Cells through Inhibiting P21 Expression","volume":"26","author":"Gai","year":"2021","journal-title":"J. BUON"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"8668","DOI":"10.1007\/s12035-024-04080-0","article-title":"EZH2 Promotes Glioma Cell Proliferation, Invasion, and Migration via Mir-142-3p\/KCNQ1OT1\/HMGB3 Axis: Running Title: EZH2 Promotes Glioma Cell Malignant Behaviors","volume":"61","author":"Zhang","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"12129","DOI":"10.18632\/aging.202923","article-title":"Long Noncoding RNA DLGAP1-AS1 Promotes the Progression of Glioma by Regulating the miR-1297\/EZH2 Axis","volume":"13","author":"Liu","year":"2021","journal-title":"Aging"},{"key":"ref_80","first-page":"4382","article-title":"LncRNA FOXD2-AS1 Stimulates Glioma Progression through Inhibiting P53","volume":"24","author":"Zhao","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41417-020-00263-8","article-title":"LncRNA ANCR Promotes Glioma Cells Invasion, Migration, Proliferation and Inhibits Apoptosis via Interacting with EZH2 and Repressing PTEN Expression","volume":"28","author":"Cheng","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"7309","DOI":"10.1002\/cam4.5517","article-title":"LncRNA SPRY4-IT1 Facilitates Cell Proliferation and Angiogenesis of Glioma via the miR-101-3p\/EZH2\/VEGFA Signaling Axis","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s13258-021-01117-9","article-title":"MiR-137 Inhibits the Proliferation, Invasion and Migration of Glioma via Targeting to Regulate EZH2","volume":"43","author":"Gu","year":"2021","journal-title":"Genes Genom."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"17715","DOI":"10.1038\/s41598-026-48884-7","article-title":"PSMC2 Serves as a Potential Regulatory Target of EZH2 in Promoting Glioma Progression via Epithelial-Mesenchymal Transition","volume":"16","author":"Zhu","year":"2026","journal-title":"Sci. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41419-024-06920-2","article-title":"PRMT6 Facilitates EZH2 Protein Stability by Inhibiting TRAF6-Mediated Ubiquitination Degradation to Promote Glioblastoma Cell Invasion and Migration","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Wang, J., and Wang, G.G. (2020). No Easy Way Out for EZH2: Its Pleiotropic, Noncanonical Effects on Gene Regulation and Cellular Function. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249501"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Zimmerman, S.M., Lin, P.N., and Souroullas, G.P. (2023). Non-Canonical Functions of EZH2 in Cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1233953"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/cas.14840","article-title":"The Noncanonical Role of EZH2 in Cancer","volume":"112","author":"Huang","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1541-7786.MCR-20-0024","article-title":"Dual Regulation of Histone Methylation by mTOR Complexes Controls Glioblastoma Tumor Cell Growth via EZH2 and SAM","volume":"18","author":"Harachi","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"565","DOI":"10.18632\/oncotarget.13478","article-title":"EZH2 Overexpression Is Associated with Poor Prognosis in Patients with Glioma","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/jcmm.16149","article-title":"EZH2 Is a Potential Prognostic Predictor of Glioma","volume":"25","author":"Chen","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Wong, Y.P., Che Abdul Aziz, R., Noor Aizuddin, A., Mohd Saleh, M.F., Mohd Arshad, R., and Tan, G.C. (2022). High EZH2 Protein Expression Is a Poor Prognostic Predictor in IDH1 R132H-Negative Gliomas. Diagnostics, 12.","DOI":"10.3390\/diagnostics12102383"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Peng, C., Chen, W., Yang, J., Wang, L., Lu, L., and Ge, R. (2026). Overexpression of EZH2 Is Associated with Clinicopathological Parameters and Poor Prognosis in Gliomas. Oncol. Lett., 32.","DOI":"10.3892\/ol.2026.15721"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"104397","DOI":"10.1016\/j.drudis.2025.104397","article-title":"Epigenetic Roles of Lysine-Specific Demethylase 1 (LSD1) in Cancer Metabolism","volume":"30","author":"Cheng","year":"2025","journal-title":"Drug Discov. Today"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12929-021-00737-3","article-title":"Roles of Lysine-Specific Demethylase 1 (LSD1) in Homeostasis and Diseases","volume":"28","author":"Kim","year":"2021","journal-title":"J. BioMed Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.3892\/or.2016.5099","article-title":"Stabilization of LSD1 by Deubiquitinating Enzyme USP7 Promotes Glioblastoma Cell Tumorigenesis and Metastasis through Suppression of the P53 Signaling Pathway","volume":"36","author":"Yi","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"18","DOI":"10.18632\/oncotarget.725","article-title":"KDM1 Is a Novel Therapeutic Target for the Treatment of Gliomas","volume":"4","author":"Sareddy","year":"2013","journal-title":"Oncotarget"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e202201400","DOI":"10.26508\/lsa.202201400","article-title":"ZBTB18 Inhibits SREBP-Dependent Lipid Synthesis by Halting CTBPs and LSD1 Activity in Glioblastoma","volume":"6","author":"Ferrarese","year":"2023","journal-title":"Life Sci. Alliance"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"14572","DOI":"10.18632\/oncotarget.3990","article-title":"Lysine-Specific Demethylase (LSD1\/KDM1A) and MYCN Cooperatively Repress Tumor Suppressor Genes in Neuroblastoma","volume":"6","author":"Amente","year":"2015","journal-title":"Oncotarget"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/neuonc\/noad018","article-title":"Lysine-Specific Histone Demethylase 1A (KDM1A\/LSD1) Inhibition Attenuates DNA Double-Strand Break Repair and Augments the Efficacy of Temozolomide in Glioblastoma","volume":"25","author":"Alejo","year":"2023","journal-title":"Neuro-Oncology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"E4055","DOI":"10.1073\/pnas.1501967112","article-title":"Dynamic Epigenetic Regulation of Glioblastoma Tumorigenicity through LSD1 Modulation of MYC Expression","volume":"112","author":"Kozono","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/onc.2016.395","article-title":"Novel KDM1A Inhibitors Induce Differentiation and Apoptosis of Glioma Stem Cells via Unfolded Protein Response Pathway","volume":"36","author":"Sareddy","year":"2017","journal-title":"Oncogene"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"EMBR202050193","DOI":"10.15252\/embr.202050193","article-title":"HOTAIR lncRNA Promotes Epithelial\u2013Mesenchymal Transition by Redistributing LSD1 at Regulatory Chromatin Regions","volume":"22","author":"Jarroux","year":"2021","journal-title":"EMBO Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1126\/science.1192002","article-title":"Long Noncoding RNA as Modular Scaffold of Histone Modification Complexes","volume":"329","author":"Tsai","year":"2010","journal-title":"Science"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1158\/1541-7786.MCR-17-0241","article-title":"Notch Represses Transcription by PRC2 Recruitment to the Ternary Complex","volume":"15","author":"Han","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/s12276-020-00542-2","article-title":"LSD1: More than Demethylation of Histone Lysine Residues","volume":"52","author":"Perillo","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12929-023-00952-0","article-title":"LSD1: An Emerging Face in Altering the Tumor Microenvironment and Enhancing Immune Checkpoint Therapy","volume":"30","author":"Mamun","year":"2023","journal-title":"J. BioMed Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1002\/mco2.495","article-title":"Epigenetic Regulation in Cancer","volume":"5","author":"Gu","year":"2024","journal-title":"MedComm"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.biopha.2017.01.055","article-title":"LSD1 Collaborates with EZH2 to Regulate Expression of Interferon-Stimulated Genes","volume":"88","author":"Jin","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ncb2246","article-title":"LSD1 Regulates the Balance between Self-Renewal and Differentiation in Human Embryonic Stem Cells","volume":"13","author":"Adamo","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.celrep.2016.11.032","article-title":"Deletion of the Polycomb-Group Protein EZH2 Leads to Compromised Self-Renewal and Differentiation Defects in Human Embryonic Stem Cells","volume":"17","author":"Collinson","year":"2016","journal-title":"Cell Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"595","DOI":"10.5483\/BMBRep.2022.55.12.174","article-title":"The Role of EZH1 and EZH2 in Development and Cancer","volume":"55","author":"Lee","year":"2022","journal-title":"BMB Rep."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Yun, H., Guruvaiya, P., Levurdiak, O., Basnakian, A.G., Boerma, M., Safe, S., and Kim, K. (2026). Dual Targeting of EZH2 and LSD1 Suppresses Hepatocellular Carcinoma via Disruption of Sonic Hedgehog Signaling. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27093886"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"105764","DOI":"10.1016\/j.phrs.2021.105764","article-title":"Combination LSD1 and HOTAIR-EZH2 Inhibition Disrupts Cell Cycle Processes and Induces Apoptosis in Glioblastoma Cells","volume":"171","author":"Zhao","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.cell.2007.05.022","article-title":"Functional Demarcation of Active and Silent Chromatin Domains in Human HOX Loci by Noncoding RNAs","volume":"129","author":"Rinn","year":"2007","journal-title":"Cell"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10571-024-01455-8","article-title":"Roles of HOTAIR Long Non-Coding RNA in Gliomas and Other CNS Disorders","volume":"44","author":"Ahmad","year":"2024","journal-title":"Cell Mol. Neurobiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"8353","DOI":"10.18632\/oncotarget.3229","article-title":"HOTAIR Is a Therapeutic Target in Glioblastoma","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"537","DOI":"10.18632\/oncotarget.2681","article-title":"Long Non-Coding RNA HOTAIR Promotes Glioblastoma Cell Cycle Progression in an EZH2 Dependent Manner","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.18632\/aging.102018","article-title":"Long Non-Coding RNA AGAP2-AS1 Exerts Oncogenic Properties in Glioblastoma by Epigenetically Silencing TFPI2 through EZH2 and LSD1","volume":"11","author":"Luo","year":"2019","journal-title":"Aging"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.apsb.2024.01.005","article-title":"Strategies That Regulate LSD1 for Novel Therapeutics","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"17588359241306026","DOI":"10.1177\/17588359241306026","article-title":"Exploring Oncogenic Roles and Clinical Significance of EZH2: Focus on Non-Canonical Activities","volume":"17","author":"Wozniak","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"112532","DOI":"10.1016\/j.biopha.2021.112532","article-title":"EZH2 as a New Therapeutic Target in Brain Tumors: Molecular Landscape, Therapeutic Targeting and Future Prospects","volume":"146","author":"Paskeh","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13148-021-01045-1","article-title":"Finding an Easy Way to Harmonize: A Review of Advances in Clinical Research and Combination Strategies of EZH2 Inhibitors","volume":"13","author":"Li","year":"2021","journal-title":"Clin. Epigenet."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nchembio.1084","article-title":"A Selective Inhibitor of EZH2 Blocks H3K27 Methylation and Kills Mutant Lymphoma Cells","volume":"8","author":"Knutson","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/cb500785t","article-title":"Chemical Probes of Histone Lysine Methyltransferases","volume":"10","author":"Kaniskan","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"104972","DOI":"10.1016\/j.ebiom.2024.104972","article-title":"Regulation of EZH2 Protein Stability: New Mechanisms, Roles in Tumorigenesis, and Roads to the Clinic","volume":"100","author":"Guo","year":"2024","journal-title":"eBioMedicine"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"98348","DOI":"10.18632\/oncotarget.21311","article-title":"The EZH2 Inhibitor GSK343 Suppresses Cancer Stem-like Phenotypes and Reverses Mesenchymal Transition in Glioma Cells","volume":"8","author":"Yu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Scuderi, S.A., Filippone, A., Basilotta, R., Mannino, D., Casili, G., Capra, A.P., Chisari, G., Colarossi, L., Sava, S., and Campolo, M. (2022). GSK343, an Inhibitor of Enhancer of Zeste Homolog 2, Reduces Glioblastoma Progression through Inflammatory Process Modulation: Focus on Canonical and Non-Canonical NF-\u03baB\/I\u03baB\u03b1 Pathways. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213915"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/ijc.29566","article-title":"ABCB1 and ABCG2 Restrict the Brain Penetration of a Panel of Novel EZH2-Inhibitors","volume":"137","author":"Zhang","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 Inhibitor, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Advanced Solid Tumours: A First-in-Human, Open-Label, Phase 1 Study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_131","unstructured":"(2026, August 05). Update: Ipsen Voluntarily Withdraws Tazverik\u00ae (Tazemetostat) in Follicular Lymphoma and Epithelioid Sarcoma. Available online: https:\/\/www.ipsen.com\/press-release\/update-ipsen-voluntarily-withdraws-tazverik-tazemetostat-in-follicular-lymphoma-and-epithelioid-sarcoma-3252192\/."},{"key":"ref_132","unstructured":"(2026, August 05). FDA Alerts Health Care Providers and Patients about Increased Risk of New Blood Cancers with Tazverik (Tazemetostat) Use; Sponsor to Voluntarily Withdraw Product from Market, Available online: https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fda-alerts-health-care-providers-and-patients-about-increased-risk-new-blood-cancers-tazverik."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/cb400133j","article-title":"An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1","volume":"8","author":"Konze","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.molcel.2008.11.004","article-title":"Ezh1 and Ezh2 Maintain Repressive Chromatin through Different Mechanisms","volume":"32","author":"Margueron","year":"2008","journal-title":"Mol. Cell"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41589-019-0421-4","article-title":"Discovery of a First-in-Class EZH2 Selective Degrader","volume":"16","author":"Ma","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41392-022-01240-3","article-title":"Discovery of IHMT-337 as a Potent Irreversible EZH2 Inhibitor Targeting CDK4 Transcription for Malignancies","volume":"8","author":"Mei","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"216812","DOI":"10.1016\/j.canlet.2024.216812","article-title":"EPIC-0628 Abrogates HOTAIR\/EZH2 Interaction and Enhances the Temozolomide Efficacy via Promoting ATF3 Expression and Inhibiting DNA Damage Repair in Glioblastoma","volume":"588","author":"Yang","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/neuonc\/noac242","article-title":"A Novel Compound EPIC-0412 Reverses Temozolomide Resistance via Inhibiting DNA Repair\/MGMT in Glioblastoma","volume":"25","author":"Zhao","year":"2023","journal-title":"Neuro-Oncology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1093\/neuonc\/noad102","article-title":"EPIC-0307-Mediated Selective Disruption of PRADX\u2013EZH2 Interaction and Enhancement of Temozolomide Sensitivity to Glioblastoma via Inhibiting DNA Repair and MGMT","volume":"25","author":"Xin","year":"2023","journal-title":"Neuro-Oncology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ctm2.21","article-title":"HOTAIR-EZH2 Inhibitor AC1Q3QWB Upregulates CWF19L1 and Enhances Cell Cycle Inhibition of CDK4\/6 Inhibitor Palbociclib in Glioma","volume":"10","author":"Shi","year":"2020","journal-title":"Clin. Transl. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41698-024-00653-3","article-title":"Combined Inhibition of EZH2 and CDK4\/6 Perturbs Endoplasmic Reticulum-Mitochondrial Homeostasis and Increases Antitumor Activity against Glioblastoma","volume":"8","author":"Freitag","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.18632\/oncotarget.27842","article-title":"Amalgamation of PI3K and EZH2 Blockade Synergistically Regulates Invasion and Angiogenesis: Combination Therapy for Glioblastoma Multiforme","volume":"11","author":"Mishra","year":"2020","journal-title":"Oncotarget"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1021\/acs.jmedchem.3c02053","article-title":"First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity In Vitro and In Vivo","volume":"67","author":"Sharma","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Orth, M., Albrecht, V., Seidl, K., Kinzel, L., Unger, K., Hess, J., Kreutzer, L., Sun, N., Stegen, B., and Nieto, A. (2021). Inhibition of HSP90 as a Strategy to Radiosensitize Glioblastoma: Targeting the DNA Damage Response and Beyond. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.612354"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1158\/1078-0432.CCR-21-3622","article-title":"HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E -Mutant High-Grade Glioma","volume":"28","author":"Sasame","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"120176","DOI":"10.1016\/j.lfs.2021.120176","article-title":"A Heat Shock Protein 90 Inhibitor Reduces Oncoprotein Expression and Induces Cell Death in Heterogeneous Glioblastoma Cells with EGFR, PDGFRA, CDK4, and NF1 Aberrations","volume":"288","author":"Ho","year":"2022","journal-title":"Life Sci."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.neo.2021.06.007","article-title":"EZH2i EPZ-6438 and HDACi Vorinostat Synergize with ONC201\/TIC10 to Activate Integrated Stress Response, DR5, Reduce H3K27 Methylation, ClpX and Promote Apoptosis of Multiple Tumor Types Including DIPG","volume":"23","author":"Zhang","year":"2021","journal-title":"Neoplasia"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12032-022-01683-2","article-title":"Unique Combinations of Epigenetic Modifiers Synergistically Impair the Viability of the U87 Glioblastoma Cell Line While Exhibiting Minor or Moderate Effects on Normal Stem Cell Growth","volume":"39","author":"Alexanian","year":"2022","journal-title":"Med. Oncol."},{"key":"ref_149","first-page":"283","article-title":"The Synergistic Effect of DZ-NEP, Panobinostat and Temozolomide Reduces Clonogenicity and Induces Apoptosis in Glioblastoma Cells","volume":"56","author":"Urdiciain","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3892\/ijo.2021.5177","article-title":"APR-246 Combined with 3-Deazaneplanocin A, Panobinostat or Temozolomide Reduces Clonogenicity and Induces Apoptosis in Glioblastoma Cells","volume":"58","author":"Urdiciain","year":"2021","journal-title":"Int. J. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Korleski, J., Sudhir, S., Rui, Y., Caputo, C.A., Sall, S., Johnson, A.L., Khela, H.S., Madhvacharyula, T., Rasamsetty, A., and Li, Y. (2024). miR-217-5p NanomiRs Inhibit Glioblastoma Growth and Enhance Effects of Ionizing Radiation via EZH2 Inhibition and Epigenetic Reprogramming. Cancers, 17.","DOI":"10.3390\/cancers17010080"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"10555","DOI":"10.1038\/s41598-019-47066-y","article-title":"Transcriptome Profiling-Based Identification of Prognostic Subtypes and Multi-Omics Signatures of Glioblastoma","volume":"9","author":"Park","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.canlet.2017.10.015","article-title":"Novel Combination of Histone Methylation Modulators with Therapeutic Synergy against Acute Myeloid Leukemia in Vitro and in Vivo","volume":"413","author":"Wen","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41420-024-02105-0","article-title":"EZH2\u2013STAT3 Signaling Pathway Regulates GSDMD-Mediated Pyroptosis in Glioblastoma","volume":"10","author":"Yu","year":"2024","journal-title":"Cell Death Discov."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2019.11.009","article-title":"The Blood-Brain Barrier: Physiology and Strategies for Drug Delivery","volume":"165\u2013166","author":"Pandit","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2147\/IJN.S189871","article-title":"Targeting EZH2 for Glioma Therapy with a Novel Nanoparticle\u2013siRNA Complex","volume":"14","author":"Wang","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Lai, G., Wu, H., Yang, K., Hu, K., Zhou, Y., Chen, X., Fu, F., Li, J., Xie, G., and Wang, H.-F. (2024). Progress of Nanoparticle Drug Delivery System for the Treatment of Glioma. Front. Bioeng. Biotechnol., 12.","DOI":"10.3389\/fbioe.2024.1403511"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"8689","DOI":"10.1039\/D4NR01056F","article-title":"Recent Advances in Targeted Drug Delivery for the Treatment of Glioblastoma","volume":"16","author":"Mao","year":"2024","journal-title":"Nanoscale"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Piwowarczyk, L., Mlynarczyk, D.T., Krajka-Ku\u017aniak, V., Majchrzak-Celi\u0144ska, A., Budzianowska, A., Tomczak, S., Budzianowski, J., Wo\u017aniak-Braszak, A., Pietrzyk, R., and Baranowski, M. (2022). Natural Compounds in Liposomal Nanoformulations of Potential Clinical Application in Glioblastoma. Cancers, 14.","DOI":"10.3390\/cancers14246222"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Grzegorzewski, J., Michalak, M., Wo\u0142oszczuk, M., Bulicz, M., and Majchrzak-Celi\u0144ska, A. (2025). Nanotherapy of Glioblastoma\u2014Where Hope Grows. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26051814"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"215899","DOI":"10.1016\/j.canlet.2022.215899","article-title":"DNMT and EZH2 Inhibitors Synergize to Activate Therapeutic Targets in Hepatocellular Carcinoma","volume":"548","author":"Zhang","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Chomiak, A.A., Wiseman, A.K., Hrit, J.A., Liu, Y., Stransky, S., Cui, Y., Kong, X., Topper, M.J., Baylin, S.B., and Sidoli, S. (2026). EZH1-Dependent H3K27me1 Is an Adaptive Chromatin Barrier That Limits DNMT Inhibitor Response in Colorectal Cancer. bioRxiv.","DOI":"10.1101\/2025.09.16.676613"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Noce, B., Di Bello, E., Fioravanti, R., and Mai, A. (2023). LSD1 Inhibitors for Cancer Treatment: Focus on Multi-Target Agents and Compounds in Clinical Trials. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1120911"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"vdaf246","DOI":"10.1093\/noajnl\/vdaf246","article-title":"Combined Inhibition of Lysine-Specific Demethylase 1 and Kinase Signaling as a Preclinical Treatment Strategy in Glioblastoma","volume":"7","author":"Stitzlein","year":"2025","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/neuonc\/nov041","article-title":"Preclinical Activity of Combined HDAC and KDM1A Inhibition in Glioblastoma","volume":"17","author":"Singh","year":"2015","journal-title":"Neuro Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/leu.2013.288","article-title":"EZH2 in Normal and Malignant Hematopoiesis","volume":"28","author":"Lund","year":"2014","journal-title":"Leukemia"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1182\/blood-2011-03-340554","article-title":"Dependency on the Polycomb Gene Ezh2 Distinguishes Fetal from Adult Hematopoietic Stem Cells","volume":"118","author":"Mishima","year":"2011","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1523\/JNEUROSCI.4129-13.2014","article-title":"Ezh2 Regulates Adult Hippocampal Neurogenesis and Memory","volume":"34","author":"Zhang","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41408-025-01266-0","article-title":"Dual Targeting of EZH2 and EZH1 Drives Exit of Leukemia Stem Cells from Quiescence and Potentiates Chemotherapy in Acute Myeloid Leukemia","volume":"15","author":"Akiyama","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/cas.13326","article-title":"Novel Orally Bioavailable EZH1\/2 Dual Inhibitors with Greater Antitumor Efficacy than an EZH2 Selective Inhibitor","volume":"108","author":"Honma","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1158\/1078-0432.CCR-16-2735","article-title":"Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition","volume":"23","author":"Rizq","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e00633","DOI":"10.7554\/eLife.00633","article-title":"Histone Demethylase Lsd1 Represses Hematopoietic Stem and Progenitor Cell Signatures during Blood Cell Maturation","volume":"2","author":"Kerenyi","year":"2013","journal-title":"eLife"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13619-021-00092-6","article-title":"Coordination of EZH2 and SOX2 Specifies Human Neural Fate Decision","volume":"10","author":"Zhao","year":"2021","journal-title":"Cell Regen."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41419-025-07951-z","article-title":"Lysine-Specific Demethylase 1 Regulates Hematopoietic Stem Cell Expansion and Myeloid Cell Differentiation","volume":"16","author":"Staehle","year":"2025","journal-title":"Cell Death Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7749\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:04:01Z","timestamp":1788858241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":175,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27177749"],"URL":"https:\/\/doi.org\/10.3390\/ijms27177749","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]}}}